20240178: A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
- Title
- A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
- Principal Investigator
- Almubarak, Mohammed
- Phase
- III
- Age Group
- Adult
- Applicable Disease Sites
- Lung Cancer
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Rachel Harper
- Clinical Research Specialist
- Phone: +1 304-293-6066
- Email: rachel.harper@hsc.wvu.edu